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Case description
A 64-year-old kidney transplant recipient developed sudden, 
profound, muscle weakness in all extremities during a busi-
ness trip to Berlin. On examination, the patient was awake, 
oriented, had normal cranial nerve function, and no sensory 
defects. His past medical history revealed focal-segmental 
glomerulosclerosis at the age of 5 years and kidney trans-
plantations in 1988 and 2007. He had been on hemodialysis 
for two years and had had mild hypertension for more than 
30 years. He received standard immunosuppression (meth-
ylprednisolone, mycophenolate mofetil, and Cyclosporin A 
(CyA)) complemented by simvastatin and an ACE inhibitor 
for mild hypertension.
Labs:
Creatinine 3.3 mg/dL (Baseline 1.7 mg/dL).
CK 77,000 U/L (with < 2% MB).
Myoglobin 23,700 µg/mL.
Troponin T (high-sensitive) 136 ng/L.
GOT 290 U/L
GPT 109 U/L
Myositis was presumed and 3 g methylprednisolone was 
administered. A quadriceps biopsy showed muscle cell 
necrosis without inflammation. An autoimmune “myositis 
panel” (including ANA, dsDNA, ENA, and anti-synthetase 
antibodies) returned negative. Because combined CyA and 
statin treatment can cause rhabdomyolysis, both were dis-
continued. Skeletal muscle enzymes normalized over three 
weeks. At this time Troponin T increased to > 10,000 ng/L 
with only slightly elevated CK (237 U/L, 23% MB) and 
normal GOT and GPT. The patient did not have angina or 
ST-elevations in his electrocardiogram. The patient’s elec-
trocardiogram did not show angina or ST-elevations. Echo-
cardiography revealed an 18 mm septum without regional 
wall kinetic abnormalities and preserved ejection fraction. 
A heart muscle biopsy was performed.
What is the cause of this patient’s tremendous 
troponinemia? What are your diagnostic tests 
to establish a diagnosis?
Case solution
The patient recovered from rhabdomyolysis only to sub-
sequently develop cardiac muscle lysis. Establishing the 
underlying cause for the skeletal myocyte damage was rather 
straightforward. Inflammatory myositis was ruled out in 
the muscle biopsy and toxic rhabdomyolysis was assumed, 
most likely from interactions between CyA and the statin. In 
contrast, elucidating the cause of the massive troponinemia 
indicating cardiac muscle breakdown was challenging but 
also educating education.
We excluded coronary artery occlusion via cardiac cath-
eterization and considered the possibility of storage disease 
given the 18 mm interventricular septum with only mild 
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hypertension. Endomyocardial biopsies established lympho-
cytic myocarditis, and a nested PCR detected human CMV 
DNA in the biopsy material confirmed by direct sequenc-
ing. Subsequently, we amplified CMV DNA from plasma, 
and detected CMV IgM and IgG antibodies indicating CMV 
reactivation or reinfection. With current prophylactic and 
preemptive antiviral treatment strategies, CMV disease 
occurs in approximately 15–30% of kidney allograft recipi-
ents at high risk within the first year after transplantation. 
Our patient had an unusual disease course in that CMV dis-
ease occurred 13 years after his second transplantation with 
a rather uncommon organ manifestation, namely myocar-
ditis. A recent review described only 7 CMV myocarditis 
cases after solid-organ transplantation [1]. High-dose ster-
oids administered shortly after admission possibly contrib-
uted to CMV reactivation in our patient. Could myocarditis 
explain such a high troponin T level? Lauer et al. found 
that Troponin T was more sensitive than CK and CK-MB in 
myocarditis [2]. The highest Troponin T level in their series 
was 8820 ng/L, somewhat lower than in our patient.
Our second major histological finding was a strong inter-
stitial and vascular deposition of amyloid in the myocardium 
with typical birefringence (Fig. 1) and strong reactivity for 
serum amyloid A (SAA) that possibly explains the discrep-
ancy between mild hypertension and the markedly increased 
septum thickness. Nevertheless, why would this patient 
have de novo cardiac SAA? Only 11 of the 5112 amyloi-
dosis patients from a large database developed de novo AA 
amyloidosis post transplantation, nine of whom were kidney 
transplant recipients [3]. Six of the eleven patients had renal, 
and none had cardiac amyloidosis. Did cardiac amyloido-
sis contribute to the tremendous Troponin T level in our 
patient? Cardiac AL amyloidosis caused increased Troponin 
T levels in two-thirds of the patients, but the reported lev-
els were only mildly elevated [4]. Conceivably, the cardiac 
amyloidosis was synergistic with the myocarditis explaining 
these extremely high Troponin T values in our patient.
Our patient had none of the inflammatory diseases com-
monly associated with AA amyloidosis [5]. The authors 
of this review acknowledge that an idiopathic rest group 
remains and suggest that SAA1.1 genotyping will eventu-
ally reveal common characteristics in this group. Our patient 
indeed carried a homozygous SAA1α gene mutation that is 
associated with a 3–sevenfold higher AA amyloidosis risk in 
Caucasians [6, 7]. Conceivably, his AA amyloidosis resulted 
from chronic inflammation that frequently occurs in immu-
nosuppressed transplant patients together with his genetic 
predisposition. His persistently increased SAA protein and 
CRP levels support this assumption.
Finally, we suggest that SAA contributed to the extensive 
muscle wasting in our patient that made eGFR determina-
tions impossible. Skeletal muscles express SAA1 receptors 
and binding of SAA1 activates NF-κB in myocytes [8]. 
NF-κB in turn mediates muscle atrophy and expression 
of the atrogenes Trim63/MuRF1, Fbxo32/Atrogin1, and 
Fbxo30/MuSA1. Such an inflammatory SAA-driven molec-
ular mechanism possibly contributed to our patient’s rapid 
muscle atrophy.
Fig. 1  Endomyocardial biop-
sies. (a) Lymphocytic inflam-
mation with numerous  CD3+ 
T cells (× 200), (b) myocardial 
deposition of Congo-red mate-
rial with (c) typical birefrin-
gence by polarized microscopy, 
(d) and serum amyloid A reac-
tivity by immunohistochemical 
stainings (× 400)
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Follow‑up
The patient improved after Valganciclovir was initiated. 
CMV copy number and troponin T declined slowly. He was 
able to leave the hospital on a walker.
Conclusions
Our patient highlights the importance of toxic drug inter-
actions, inflammatory disorders, and genetic modifiers, all 
encountered in solid-organ transplantation.
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